Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Solid Tumor × ulocuplumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Waldenstrom Macroglobulinemia 1 Solid Tumor 1 Recurrence 1 Multiple Myeloma 1 Lymphoma, Follicular 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1

Interventions

pembrolizumab 12 Injections 12 Paclitaxel 10 Docetaxel 9 Cisplatin 8 senaparib 7 Nivolumab 7 Capecitabine 7 Bevacizumab 7 toripalimab 6 atezolizumab 6 Irinotecan 6 Cyclophosphamide 6 tislelizumab 5 Fluorouracil 5 fludarabine 4 apatinib 4 Leucovorin 4 Ipilimumab 4 Gemcitabine 4 Fluorodeoxyglucose F18 4 spartalizumab 3 pertuzumab 3 olaparib 3 camrelizumab 3 Rifampin 3 Radiosurgery 3 Oxaliplatin 3 Midazolam 3 Itraconazole 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02472977 2018-11-01

CXCessoR4

Bristol-Myers Squibb

Phase 1/2 Terminated

61 enrolled 11 charts

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡